What the FDA labels say about taking them together
Pimozide and ziprasidone
Pimozide's FDA label of August 12, 2026 names ziprasidone in its drug interactions section, and ziprasidone's label names pimozide too. The pimozide label: “… trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects.”
Check it at the source: the pimozide FDA label on DailyMed (effective August 12, 2026, Par Health USA, LLC); the ziprasidone FDA label on DailyMed (effective July 20, 2026, Apotex Corp.).
What does the pimozide label say about ziprasidone?
Pimozide label, drug interactionsAccordingly, pimozide should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects.
Source: FDA drug label (Pimozide), Par Health USA, LLC, effective August 12, 2026 (SPL set 70b079e2-a1f7-4a93-8685-d60a4d7c1280), via openFDA; the full label on DailyMed
What does the ziprasidone label say about pimozide?
Ziprasidone label, contraindicationsTherefore, ziprasidone should not be given with: dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol or tacrolimus. other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning [see Warnings and Precautions (5.3) ].
Source: FDA drug label (ziprasidone hydrochloride), Apotex Corp., effective July 20, 2026 (SPL set ccfd5ba2-7271-f3dd-4c98-7418c1a4b54a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Pimozide | Ziprasidone | |
|---|---|---|
| Labeled for | n/a | Bipolar disorder, Schizophrenia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1.23 per tablet 1 mg tablet | $0.269 per capsule 20 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once